Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: Before the molecular targeting therapy era

Japanese Journal of Clinical Oncology

Volumn 39, Issue 5, 2009, Pages 310-314

  Kai, Fumitake ^a   Takayama, Tatsuya ^a   Sugiyama, Takayuki ^a   Furuse, Hiroshi ^a   Mugiya, Soichi ^a   Ozono, Seiichiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

IFN ; Prognostic factor; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PROGNOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 65549088865     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp022     Document Type: Article

References (15)

1. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008;44:2152-61.
2. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients. Eur Urol 2009 (January 3, Epub ahead of print).
3. Union international Contre le Cancer. TNM Atlas. 4th edn. Berlin: Springer-Verlag 1997.
4. The Japanese Urological Association, the Japanese Society of Pathology, and Japan Radiological Society. General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma. 3rd edn. Tokyo: Kanehara & Co., Ltd 1999.
5. Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K. Prognostic factors of renal cell carcinoma-a multivariate analysis. J Surg Oncol 1998;68:11-8.
6. Takashi M, Nakano Y, Sakata T, Miyake K, Hamajima N. Multivariate evaluation of prognostic determinants for renal cell carcinoma. Urol Int 1993;50:6-12.
7. Thrasher JB, Paulson DF. Prognostic factor in renal cancer. Urol Clin North Am 1993;20:247-62.
8. Strohmeyer T, Ackermann R. Classic and modern prognostic indication in renal cell carcinoma. Urol Int 1991;47:203-12.
9. Selli C, Hinshaw WM, Woodard BH, Paulson DF. Stratification of risk factors in renal cell carcinoma. Cancer 1983;52:899-903.
10. Nurmi M. Prognostic factor in renal cell carcinoma. An evaluation of operative findings. Br J Urol 1984;56:270-5.
11. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145-1154.
12. Masuda H, Kurita Y, Suzuki A, Kanbayashi T, Suzuki K, Fujita K. Prognostic factors for renal cell carcinoma: A multivariate analysis of 320 cases. Int J Urol 1997;4:247-53.
13. Gotoh A, Shirakawa T, Hinata N, Wada Y, Hara I, Fujisawa M, et al. Long-term outcome of postoperative interferon-α adjuvant therapy for non-metastatic renal cell carcinoma. Int J Urol 2004;11:257-63.
14. Basting R, Corvin S, Händel D, Hinke A, Schmidt D. Adjuvant immunotherapy in renal cell carcinoma-comparison of interferon alpha treatment with an untreated control. Anticancer Res 1999;19-2c:1545-8.
15. Migliari R, Muscas G, Solinas A, Melis M, Ionta MT, Massidda B, et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J Chemother 1995;7-3:240-5.